Skip to main content
. Author manuscript; available in PMC: 2021 Sep 3.
Published in final edited form as: Cell. 2020 Sep 3;182(5):1311–1327.e14. doi: 10.1016/j.cell.2020.07.040

Figure 2. Definition of High-confidence Biomarkers for the Prediction of SaB Patient Mortality.

Figure 2

(A) Top 25 EFS proteins (survival vs. mortality; ER_RF - error-rate based, Gini_RF - Gini index random forests). (B) Abundance and ROC curve of Fetuin B (survival vs. mortality). (C) Abundance and ROC curve of SVEP1 (survival vs. mortality). (D) Top 25 EFS metabolites (survival vs. mortality). (E) Abundance and ROC curve of metabolite ID-349 (survival vs. mortality). (F) Abundance and ROC curve of metabolite ID-854 (survival vs. mortality). (G) Dual-omic ROC curve (survival vs. mortality; Protein: FETUB; Metabolite: ID-349; Combo: FETUB + IGFBP3 + ID-349 + ID-854). (H) ELISA abundance and ROC curve of Fetuin B (survival vs. mortality). (I) Survival curves of Fetuin B high (>2.2 μg/ml) and low (<2.2 μg/ml) patients. (J) Metadata assessment of Fetuin B. For B, C, E and F, Kruskal-Wallis tests with Dunn’s multiple comparison test significance is displayed. For H, MWU tests significance is displayed.